Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News JOHNSON & JOHNSON JNJ

Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more

Recent & Breaking News (NYSE:JNJ)

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

PR Newswire April 5, 2024

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.

PR Newswire April 5, 2024

Johnson & Johnson to Acquire Shockwave Medical

Business Wire April 5, 2024

Johnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation

Business Wire April 4, 2024

Johnson & Johnson to Participate in the BofA Securities Health Care Conference

Business Wire April 2, 2024

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

GlobeNewswire March 12, 2024

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Business Wire March 11, 2024

Johnson & Johnson Completes Acquisition of Ambrx

Business Wire March 7, 2024

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

PR Newswire March 1, 2024

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

PR Newswire February 20, 2024

Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference

Business Wire February 14, 2024

Johnson & Johnson to Participate in the Leerink Global Biopharma Conference

Business Wire February 12, 2024

Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference

Business Wire February 2, 2024

AMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

PR Newswire January 26, 2024

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

Business Wire January 23, 2024

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Business Wire January 8, 2024

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024

Business Wire January 2, 2024

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Business Wire December 11, 2023

Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire December 7, 2023

Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review

Business Wire December 5, 2023